Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Canadian approval typically follows FDA decisions within six to twelve months
GLP-1 Agonist provides both visible weight loss results and meaningful improvements to health and quality of life
Existing studies are generally small in sample size and limited in follow-up duration
The company narrowed its full-year revenue guidance to a range of $2.335 billion to $2.355 billion and adjusted EBITDA guidance to $307 million to $317 million
Tirzepatide has a well-characterized half-life of approximately 5 days (120 hours)
US$ 23.72
US$ 22.77
US$ 23.47
US$ 24.59
US$ 28.12
US$ 23.79
